

# Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision<sup>i</sup>

Actives substances(s): decitabine, cedazuridine

Latest Decision number(s): 1) P/0543/2023

Corresponding PIP number(s): 1) EMEA-003071-PIP02-23

If the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies:

Yes  No

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

Treatment of myelodysplastic syndromes, including juvenile myelomonocytic leukaemia

has been discontinued

for the following reason(s): (tick all that apply)

(possible) lack of efficacy in adults

(possible) lack of efficacy in children

(possible) unsatisfactory safety profile in adults

(possible) unsatisfactory safety profile in children

commercial reasons (please specify: )

manufacturing / quality problems

other regulatory action (please specify: Type II variation application was withdrawn. )

other reason (please specify: )

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation:

On 15 Dec 2023, the applicant submitted to EMA a variation (EMA/H/C/005823/II/0002) to extend the indication for INAQOVI to include treatment of adult patients with myelodysplastic syndromes (MDS) and treatment of adult patients with chronic myelomonocytic leukaemia (CMML). Following the interactions with the CHMP during above mentioned procedure, the applicant withdrew the application. Therefore, the applicant would like to take this opportunity to remove the MDS and JMML indication from the PIP.

Date: 04/07/2025

Contact for inquiries from interested parties:

Telephone: +49 (0) 173 3741318

Email: [paediatrics-info@otsuka-europe.com](mailto:paediatrics-info@otsuka-europe.com)

---

<sup>i</sup> This form will be published to the corresponding decision available on the website of the European Medicines Agency.